The discovery and development of belimumab: the anti-BLyS-lupus connectionSTOHL, William; HILBERT, David M.Nature biotechnology (Print). 2012, Vol 30, Num 1, pp 69-77, issn 1087-0156, 9 p.Article

The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteersSHIDA, Y; TAKAHASHI, N; SAKAMOTO, T et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 1, pp 97-101, issn 0269-4727, 5 p.Article

Neue Anti-B-Zell-Strategien für die Therapie rheumatischer Erkrankungen : Anti-B-Zell-Strategien für Autoimmunerkrankungen = Novel B-cell directed strategies for the treatment of rheumatic diseases : Anti-B-cell strategies in autoimmune diseasesTARNER, I. H.Zeitschrift für Rheumatologie (Print). 2009, Vol 68, Num 5, issn 0340-1855, 380-389 [9 p.]Article

Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulatorAUYEUNG-KIM, Diana J; DEVALARAJA, Madhav N; MIGONE, Thi-Sau et al.Reproductive toxicology (Elmsford, NY). 2009, Vol 28, Num 4, pp 443-455, issn 0890-6238, 13 p.Article

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseVOLLENHOVEN, Ronald F.van; PETRI, Michelle A; CERVERA, Ricard et al.Annals of the rheumatic diseases. 2012, Vol 71, Num 8, pp 1343-1349, issn 0003-4967, 7 p.Article

Belimumab: Review of Use in Systemic Lupus ErythematosusBOYCE, Eric G; FUSCO, Bryan E.Clinical therapeutics. 2012, Vol 34, Num 5, pp 1006-1022, issn 0149-2918, 17 p.Article

Belimumab: A BLyS-Specific Inhibitor for Systemic Lupus ErythematosusWIGLESWORTH, Amy K; ENNIS, Kelly M; KOCKLER, Denise R et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 12, pp 1955-1961, issn 1060-0280, 7 p.Article

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus ErythematosusGINZLER, Ellen M; WALLACE, Daniel J; FREIMUTH, William W et al.Journal of rheumatology. 2014, Vol 41, Num 2, pp 300-309, issn 0315-162X, 10 p.Article

A Randomized Controlled Trial of Belimumab for the Treatment of Active Systemic Lupus ErythematosusGAMBLE, Ryan G; DELLAVALLE, Robert P.Archives of dermatology (1960). 2012, Vol 148, Num 3, pp 376-378, issn 0003-987X, 3 p.Article

Belimumab for Systemic Lupus ErythematosusHANNAHS HAHN, Bevra.The New England journal of medicine. 2013, Vol 368, Num 16, pp 1528-1535, issn 0028-4793, 8 p.Article

Long-Term Safety Profile of Belimumab Plus Standard Therapy in Patients With Systemic Lupus ErythematosusMERRILL, Joan T; GINZLER, Ellen M; PINEDA, Lilia et al.Arthritis and rheumatism. 2012, Vol 64, Num 10, pp 3364-3373, issn 0004-3591, 10 p.Article

Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus ErythematosusDENNIS, G. J.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 1, pp 143-149, issn 0009-9236, 7 p.Article

Belimumab Reduces Autoantibodies, Normalizes Low Complement Levels, and Reduces Select B Cell Populations in Patients With Systemic Lupus ErythematosusSTOH, William; HIEPE, Falk; PINEDA, Lilia et al.Arthritis and rheumatism. 2012, Vol 64, Num 7, pp 2328-2337, issn 0004-3591, 10 p.Article

Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging StudySTOHL, William; MERRILL, Joan T; MCKAY, James D et al.Journal of rheumatology. 2013, Vol 40, Num 5, pp 579-589, issn 0315-162X, 11 p.Article

Maladies auto-immunes et systémiques = Autoimmune and systemic diseaseMICELI-RICHARD, Corinne.La Lettre du rhumatologue. 2011, Num 368, issn 0761-5027, 44-51 [6 p.]Article

Primary Sjogren syndrome: an update on current pharmacotherapy options and future directionsBRITO-ZERON, Pilar; SISO-ALMIRALL, Antoni; BOVE, Albert et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 3, pp 279-289, issn 1465-6566, 11 p.Article

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 TrialWINN CHATHAM, W; WALLACE, Daniel J; ZHONG, Z. John et al.Journal of rheumatology. 2012, Vol 39, Num 8, pp 1632-1640, issn 0315-162X, 9 p.Article

A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients With Systemic Lupus ErythematosusFURIE, Richard; PETRI, Michelle; STOHL, William et al.Arthritis and rheumatism. 2011, Vol 63, Num 12, pp 3918-3930, issn 0004-3591, 13 p.Article

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus ErythematosusWALLACE, Daniel J; STOHL, William; FERNANDEZ, Vivian et al.Arthritis care and research. 2009, Vol 61, Num 9, pp 1168-1178, issn 0893-7524, 11 p.Article

Les biothérapies dans le lupus érythémateux disséminé et les connectivités : nouvelles thérapeutiques : Rhumatologie = Treatment of connective tissue diseases with biological agentsSO, Alexander.Revue médicale suisse. 2008, Vol 4, Num 149, issn 1660-9379, 707-710 [3 p.]Article

Bélimumab (BENLYSTA°): Des risques d'immunodépression, sans efficacité tangible établieLa Revue Prescrire. 2013, Vol 33, Num 354, issn 0247-7750, p. 258Article

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsMANZI, Susan; SANCHEZ-GUERRERO, Jorge; JOHN ZHONG, Z et al.Annals of the rheumatic diseases. 2012, Vol 71, Num 11, pp 1833-1838, issn 0003-4967, 6 p.Article

Belimumab: In Systemic Lupus ErythematosusBURNESS, Celeste B; MCCORMACK, Paul L.Drugs (Basel). 2011, Vol 71, Num 18, pp 2435-2444, issn 0012-6667, 10 p.Article

Emerging biological therapies in primary Sjögren's syndromeRAMOS-CASALS, M; BRITO-ZERON, P.Rheumatology (Oxford. Print). 2007, Vol 46, Num 9, pp 1389-1396, issn 1462-0324, 8 p.Article

Belimumab conte le lupus érythémateux disséminé = Belimumab (Benlysta) for Systemic Lupus ErythematosusThe Medical letter on drugs and therapeutics (Edition française). 2011, Vol 33, Num 14, pp 53-54, issn 0253-8512, 2 p.Article